SCHEMBL8041585

SCHEMBL8041585

Nc1cc(Cl)c(NCCc2c[nH]c3ccccc23)c(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.59
SLC2A1 P11166 1/20 0.59
RAD52 P43351 1/20 0.59
KMT2A Q03164 1/20 0.59
HTR2A P28223 8/20 0.56
HTR6 P50406 7/20 0.56
HTR1A P08908 6/20 0.56
HTR7 P34969 6/20 0.56
DRD2 P14416 5/20 0.56
GPR84 Q9NQS5 1/20 0.54
GOT1 P17174 3/20 0.54
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HTT P42858 1/20 0.54
MC5R P33032 1/20 0.52
MC3R P41968 1/20 0.52
MC1R Q01726 1/20 0.52
CDK2 P24941 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18784064 0.87 KMT2A (0.59) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL13130733 0.84 KMT2A (0.59) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL18531428 0.82 CDK2 (0.65) POLBSLC2A1RAD52KMT2AHTR6
SCHEMBL18531430 0.82 CDK2 (0.54) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL13130734 0.81 MAPT (0.56) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL8040876 0.81 HTR2A (0.58) KMT2AHTR2AHTR6CDK2CYP1A2
SCHEMBL8047123 0.80 KMT2A (0.54) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL12810783 0.80 CDK2 (0.52) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL8263255 0.78 HTR2A (0.65) POLBSLC2A1RAD52KMT2AHTR2A
SCHEMBL8044543 0.77 HTR2A (0.54) POLBSLC2A1RAD52KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2023-02-21 US disclosed
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 JANSSEN PHARMACEUTICA NV (BE) 2020-04-23 US disclosed
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2017-04-27 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
WO-2009037308-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 POLB 1537/4885SLC2A1 4527/4885RAD52 502/4885
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 TP53, MDM2, TP53BP1 POLB 1537/4885SLC2A1 4527/4885RAD52 502/4885
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 TP53, MDM2, TP53BP1 POLB 1537/4885SLC2A1 4527/4885RAD52 502/4885
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 TP53, MDM2, TP53BP1 POLB 1301/4885SLC2A1 4586/4885RAD52 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.